CAMP4 Therapeutics

Pleased to have participated in @HCWCO’s 4th Annual BioConnect Investor Conference, where our CEO, Josh Mandel-Brehm, joined a fireside chat to discuss our #regRNA-targeting approach to increase #GeneExpression for diseases like #SYNGAP1. Tune in here: bit.ly/3PAWJtK

Our CAMPers took intentional time offsite to step back, spark ideas, & reconnect as a team to fuel innovation ahead. We recognized this year’s Mountaineer & Sherpa Award recipients, celebrating leadership, collaboration, & contributions moving us forward. Thank you to our team!

We’re excited to announce we will present new preclinical data at @TIDESInforma’s #TIDESUSA. Join us in Boston as we highlight our lead candidate’s ability to improve seizure threshold & severity in a #SYNGAP1 model. Read more in our press release: bit.ly/49MXR4l

Attending @LifeSciEvents' #FierceBiotechWeek? Hear from our CFO, Kelly Gold, on how we are approaching R&D strategy in today’s capital-disciplined market, prioritizing programs, building partnerships, & advancing our pipeline in haploinsufficient diseases: bit.ly/4cAl1wU

Today, we announced our Q1 2026 financial results and corporate highlights. Read more in our press release: bit.ly/4nh9bv5

Pleased to take part in @GeneticEpilepsy's GETA Conference & @CureSyngap's SYNGAP1 Symposium! These gatherings offered an opportunity to connect with the #SYNGAP1 & #Epilepsy communities, alongside researchers, clinicians, & advocates. Thank you to all for the impactful events!

We're proud to sponsor the @GeneticEpilepsy's GETA Conference, where our CMO, Yuri Maricich MD will be presenting. Excited to connect & discuss how our lead therapeutic candidate could restore protein production to address #SYNGAP1 at its root. Learn more: bit.ly/4sQwgXv

We’re proud to join the SYNGAP1 Symposium by @cureSYNGAP1. Our CMO, Yuri Maricich, MD, & CBOO, Caleb Moore, will engage with families, listen to lived experiences, & share updates on our #regRNA approach. Understanding patient needs is key to developing meaningful therapies.

We're thrilled to share our new preprint on @bioRxivpreprint! Using our #regRNA Capture-seq technology, we built what’s believed to be the largest catalog of regRNAs ever compiled & showed how targeting them with #ASOs can increase #GeneExpression: bit.ly/4mYHs2i

The discovery of DNA's structure laid the foundation for modern science, including our work in regulatory RNA (#regRNA) targeted therapies. This #DNADay, learn how regRNA- targeted therapies could treat haploinsufficient diseases like #SYNGAP1: bit.ly/3O2chWU

Delighted to announce our CFO, Kelly Gold, was named among @Citeline's In Vivo's 2026 Rising Leaders in the life sciences sector. As we continue advancing CMP-002 into the clinic, we rely on our outstanding leaders to guide our progress. Congrats, Kelly! bit.ly/4cLkM1V

Last month, our CAMPers hit the slopes for some well- deserved fun and team bonding! ️❄️​ We value these moments to connect and celebrate the dedication our employees bring every day to advancing science and supporting our mission.

Our CFO, Kelly Gold, will present at Needham's 25th Annual Virtual Healthcare Conference to discuss our corporate highlights and updates as we progress development of CMP-002. Tune in to the virtual webcast: bit.ly/41Odwfl

Proud to sponsor @CaresBoston's 10th Annual Impact Breakfast. Join us as the life sciences community comes together to support initiatives on poverty, education, & health equity, while fostering collaborations across the healthcare field. More here: bit.ly/3QlKIbC

#ICYMI, our CSO, Dan Tardiff, PhD joined Angela Gabriel in this @BioSpace article to share insights on the complexities of drug discovery & how pioneering new science requires creativity, resourcefulness, & diverse research partnerships. Read here: bit.ly/47AsIQS

#SYNGAP1 is a rare genetic disease caused by mutations in the SYNGAP gene, leading to reduced protein levels. With ~10,000 patients in the U.S., our ASO candidates aims to upregulate gene expression to restore protein levels & improve symptoms. Learn more: bit.ly/4avbMNj

Welcome Michael MacLean to our Board of Directors! With over 35 years of experience in financial & operational leadership, Michael brings valuable expertise as we advance our regRNA-based #SYNGAP1 investigational therapy towards the clinic. Read more: bit.ly/47hwgap

This month, we joined the SYNGAP1 Family Day events in France & Spain, engaging with the #SYNGAP1 community, with our CMO, Yuri Maricich, MD, sharing insights on our #regRNA therapy. Grateful to @CureSYNGAP1 and the broader community for the continued collaboration and dialogue!

Our CFO, Kelly Gold, will participate in @Stifel’s 2026 CNS Forum. Tune in to our virtual corporate presentation tomorrow to hear her updates on our company progress in #SYNGAP1 and the CNS space. Register here: bit.ly/4uy1cNu

We’re honored to join the #SYNGAP1 Family Day symposium in Germany, bringing together families, clinicians, & researchers to discuss research & clinical trials. Our CMO, Yuri Maricich M.D. shared insights on our upcoming clinical study & the potential of our #regRNA therapeutics.